Form Type:  SC 13G
Filing Date:  2/3/2023 
CIK:  0001737287 
Address:  210 EAST GRAND AVENUE 
City, State, Zip:  SOUTH SAN FRANCISCO, California 94080 
Telephone:  (650) 457-2700 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
0.29 (5.45%)  
Trade Time: 
Jun 02  
Market Cap: 
Trade ALLO now with 

© 2023  
Description of Business
We are a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer. We are developing a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Our engineered T cells are allogeneic, meaning they are derived from healthy donors for intended use in any patient, rather than from an individual patient for that patient's use, as in the case of autologous T cells. We believe this key difference will enable us to deliver readily available treatments faster, more reliably, at greater scale, and to more patients. Chimeric antigen receptor (CAR) T cell therapy, a form of cancer immunotherapy, has emerged as a revolutionary and potentially curative therapy for patients with hematologic cancers, including refractory cancers.
Register and access this filing in:     

EDGAR® and SEC® are trademarks of the U.S. Securities and Exchange Commission. OTC Markets Group Inc.'s products and services are not affiliated with or approved by the U.S. Securities and Exchange Commission.